xRNA: A Chemically Modified RNA Platform Enabling Sustained Therapeutic Protein Expression with Cross-Species Durability
- Leveraging the xRNA™ to overcome the stability limitations of conventional mRNA, achieving an ~100-fold improvement in Area Under the Curve (AUC) through highthroughput combinatorial screening
- Demonstrating robust pharmacokinetic durability with NHP half-life Weekly xRNAencoded GLP-1 agonist (xGLP1) administration outperformed gold standard protocols of daily-dosed FDA-approved therapeutics in diet-induced obesity mice, producing substantial weight loss and improved fasting glucose
- Moreover, single-dose administration of xGLP-1 maintained significant HbA1c reduction and functional peptide levels for three weeks in genetic diabetes (db/ db mice) xRNA thus potentially, enables transformation from transient peptide administration to monthly or quarterly therapeutic regimens, utilizing a safe, titratable modality compatible with at-home patient-self-administration of intramuscular delivery